COCH PE Ratio & Valuation, Is COCH Overvalued

Historical Valuation

Envoy Medical Inc (COCH) is now in the Fair zone, suggesting that its current forward PS ratio of 95.37 is considered Fairly compared with the five-year average of -1.83. The fair price of Envoy Medical Inc (COCH) is between 0.12 to 1.33 according to relative valuation method.

Relative Value

Fair Zone

0.12-1.33

Current Price：0.77

Fair

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Envoy Medical Inc (COCH) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Envoy Medical Inc (COCH) has a current Price-to-Book (P/B) ratio of -2.20. Compared to its 3-year average P/B ratio of -7.12, the current P/B ratio is approximately -69.09% higher. Relative to its 5-year average P/B ratio of -6.16, the current P/B ratio is about -64.28% higher. Envoy Medical Inc (COCH) has a Forward Free Cash Flow (FCF) yield of approximately -85.29%. Compared to its 3-year average FCF yield of -53.65%, the current FCF yield is approximately 58.97% lower. Relative to its 5-year average FCF yield of -53.65%, the current FCF yield is about 58.97% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for COCH competitors is 36.03, providing a benchmark for relative valuation. Envoy Medical Inc Corp (COCH.O) exhibits a P/S ratio of 95.37, which is 164.67% above the industry average. Given its robust revenue growth of -25.00%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of COCH increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of COCH in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is COCH currently overvalued or undervalued?

What is Envoy Medical Inc (COCH) fair value?

COCH's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Envoy Medical Inc (COCH) is between 0.12 to 1.33 according to relative valuation method.

How does COCH's valuation metrics compare to the industry average?

The average P/S ratio for COCH's competitors is 36.03, providing a benchmark for relative valuation. Envoy Medical Inc Corp (COCH) exhibits a P/S ratio of 95.37, which is 164.67% above the industry average. Given its robust revenue growth of -25.00%, this premium appears unsustainable.

What is the current P/B ratio for Envoy Medical Inc (COCH) as of Mar 24 2026?

As of Mar 24 2026, Envoy Medical Inc (COCH) has a P/B ratio of -2.20. This indicates that the market values COCH at -2.20 times its book value.

What is the current FCF Yield for Envoy Medical Inc (COCH) as of Mar 24 2026?

As of Mar 24 2026, Envoy Medical Inc (COCH) has a FCF Yield of -85.29%. This means that for every dollar of Envoy Medical Inc's market capitalization, the company generates -85.29 cents in free cash flow.

What is the current Forward P/E ratio for Envoy Medical Inc (COCH) as of Mar 24 2026?

As of Mar 24 2026, Envoy Medical Inc (COCH) has a Forward P/E ratio of -0.65. This means the market is willing to pay $-0.65 for every dollar of Envoy Medical Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Envoy Medical Inc (COCH) as of Mar 24 2026?

As of Mar 24 2026, Envoy Medical Inc (COCH) has a Forward P/S ratio of 95.37. This means the market is valuing COCH at $95.37 for every dollar of expected revenue over the next 12 months.

COCH Valuation